For the first time in years, the acne pipeline is full with several new treatments in late stage development. If or when these get approved, it could mean the end to pimples and acne as we know them. Dimples, however, are staged for a comeback.
“Selfies are commonplace and everyone wants to look cute, friendly, and sexy in their photographs,” says Dr. Spiegel. “If you don’t have dimples to accentuate your smile, you can get them quickly with a simple office procedure. Watch for surgical dimple creation to grow in the New Year,” he predicts. The scarless procedure is known as a dimplectomy, and involves an incision inside the cheek.
Sweet Cheeks, Plump Pouts: The Year of the ‘Designer Fillers’
In East Africa
“Watch for 2017 to bring new fillers designed for specific areas of the face,” Dr. Spiegel says. Some are here already: Juvederm Voluma adds volume to the midface, while Juvederm Volbella and Restylane Lyft take aim at the lips.
“2017 will see the introduction of even more targeted products such as Restylane’s Refyne and Defyne (for smile and laugh lines),” Spiegel says. The Belotero line also comprises a host of site-specific family members. Many are already approved overseas and will likely find their way to our shores, giving cosmetic doctors an ever-expansive palette to rejuvenate and recontour the face without surgery.
Speaking of injectables, there are already three approved neuromodulators on the market – Botox Cosmetic, Dysport and Xeomin – but there are more in the pike. A new such treatment from Revance is rumored to last 7 to 8 months. “If this is reproduced in the just-starting multicenter studies, this could be a game changer for Revance and for the cosmetic field in general,” says Jeffrey S. Dover, MD, FRCPC, a Boston-based dermatologist and co-director of SkinCare Physicians in Chestnut Hill, Mass. “My belief is that patients will pay a premium for a neuromodulator that lasts 6 to 8 months over the traditional 4 months.”
Breast augmentation remains the most common plastic surgery procedure in the U.S. More than 286,200 women underwent breast enlargement surgery in 2014, a slight decline from 2013 but an increase of 35 percent since the year 2000. Silicone implants were used in 77 percent of cases, and saline implants in the remaining 23 percent.